| For: | Kim ES, Kang B. Infliximab vs adalimumab: Points to consider when selecting anti-tumor necrosis factor agents in pediatric patients with Crohn’s disease. World J Gastroenterol 2023; 29(18): 2784-2797 [PMID: 37274072 DOI: 10.3748/wjg.v29.i18.2784] |
|---|---|
| URL: | https://www.wjgnet.com/1009-3079/full/v29/i18/2784.htm |
| 编号 | Citing Articles |
| 1 |
Jeffrey Shen, Megumi Sugita, Andrea Linares-Lopez, Suma Shah, Christopher Eckstein, Elijah Lackey. Adalimumab as treatment for neurosarcoidosis: A case series. Journal of the Neurological Sciences 2024; 460 doi: 10.1016/j.jns.2024.123018
|
| 2 |
Keiko Manabe, Moe Tokunaga, Shoichi Nawachi, Yoshia Miyawaki, Takayuki Katsuyama, Yoshinori Matsumoto, Mitsuru Tsuge, Yoshio Kawakami, Shin Morizane. Juvenile‐Onset SAPHO Syndrome With Acne‐Hidradenitis Suppurativa Successfully Treated With Infliximab and Methotrexate. The Journal of Dermatology 2026; doi: 10.1111/1346-8138.70325
|
| 3 |
Rachel Gefen, Shani Y. Parnasa, Sameh Hany Emile, Nir Horesh, Justin Dourado, Zoe Garoufalia, Anjelli Wignakumar, Marylise Boutros, Steven D. Wexner. Medical therapies to prevent relapse of Crohn’s disease after surgery: a systematic review and network meta-analysis. Journal of Gastrointestinal Surgery 2025; 29(10) doi: 10.1016/j.gassur.2025.102193
|
| 4 |
Chao-Tao Tang, Fang Yin, Yitian Yin, Zide Liu, Shunhua Long, Chun-Yan Zeng, Yong Chen, You-Xiang Chen. Are Radiomic Spleen Features Useful for Assessing the Response to Infliximab in Patients With Crohn's Disease? A Multicenter Study. Clinical and Translational Gastroenterology 2024; 15(5) doi: 10.14309/ctg.0000000000000693
|
| 5 |
Yanhong Deng, Shengying Shi, Senling Feng, Xiangping Tan, Yinling Wang, Jinjin Yin, Shaozhi Liu, Yuanmei Gao. Safety of infliximab and adalimumab in pediatric inflammatory bowel diseases: a disproportionality analysis from the FAERS database. BMC Gastroenterology 2025; 25(1) doi: 10.1186/s12876-025-04154-w
|
| 6 |
F. Chelech, R. Quera, J. Saba, P. Núñez, G. Pizarro. Uso de upadacitinib en un paciente pediátrico con enfermedad de Crohn y falla primaria a adalimumab: reporte de un caso. Revista de Gastroenterología de México 2025; doi: 10.1016/j.rgmx.2025.07.012
|
| 7 |
Akshita Bhalla, Anushka Shahi , Madhurima Maity, FNU Safa, Vindlacheruvu Srividya, Ruchira Clementina, Goutham R Anugu, Salma Younas. Inflammatory Bowel Disease in Children: Current Diagnosis and Treatment Strategies. Cureus 2025; doi: 10.7759/cureus.78462
|
| 8 |
Dhayalan Kalavathy GokulRaj, Ravichandran Jayasuriya, Kunka Mohanram Ramkumar. Hydroxytyrosol from Olive Oil Mitigates Endothelial Dysfunction in Diabetic Foot Ulcers via Redox, Inflammatory, and Survival Pathways. The Journal of Nutrition 2025; 155(12) doi: 10.1016/j.tjnut.2025.09.038
|
| 9 |
Niven Wang, Abdelrahman Yousef, Kevin Nguyen, Timothy Mok, Mahmoud Yousef, Ahmed Telbany, Abu Baker Sheikh, Christopher Chang, Swathi Paleti. Safety of Live Attenuated MMR, Varicella, and Yellow Fever Vaccination in Patients with Inflammatory Bowel Disease Receiving Biologic and Targeted Synthetic Therapy: A Propensity-Score-Matched Analysis. Vaccines 2026; 14(6) doi: 10.3390/vaccines14060474
|
| 10 |
F. Chelech, R. Quera, J. Saba, P. Núñez, G. Pizarro. Upadacitinib use in a pediatric patient with Crohn’s disease and primary loss of response to adalimumab: A case report. Revista de Gastroenterología de México (English Edition) 2026; doi: 10.1016/j.rgmxen.2025.12.012
|